http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-112043699-A
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_c3e3745c63af24b22f5164e67dd84b25 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-47 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P1-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4375 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-47 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P1-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4375 |
| filingDate | 2020-08-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_74f260905ec770efd43c6ec1d542b03c http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_63665c49f875aab46210ba8ec93a0be1 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_af79e160f1601c236308eeaab4fbc090 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_76bdf070340b35eac53bb94a446afc3a http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a1b2311215f87acdc378db5e0850ede0 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_8da09f8e749735a98d80a06e5bc43c07 |
| publicationDate | 2020-12-08-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CN-112043699-A |
| titleOfInvention | A kind of pharmaceutical composition for treating chronic atrophic gastritis, medicine and application thereof |
| abstract | The invention relates to a pharmaceutical composition for treating chronic atrophic gastritis, a medicine and an application thereof, which belong to the technical field of biomedicine. The pharmaceutical composition is composed of jatrorrhizine 30-60% and evodiamine 40-70%. A medicament includes an active ingredient and a pharmaceutically acceptable carrier, wherein the active ingredient is a pharmaceutical composition. The application of a pharmaceutical composition or a medicine in the preparation of a medicine for treating CAG. The invention has the following advantages: 1. It can significantly reduce the scores of gastric mucosal atrophy, intestinal metaplasia and inflammation in CAG rats; and the therapeutic effect is significantly better than that of each monomer compound; 2. It can significantly reduce the pro-inflammatory cells in serum of CAG rats. The concentration of factors interleukin 17, chemokine 1, and the serum concentration of gastrin 17 were significantly increased; and the therapeutic effect was significantly better than that of each monomer compound. |
| priorityDate | 2020-08-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 54.